Key strengths include a differentiated radiopharmaceutical platform, substantial ongoing R&D investment, a strong strategic collaboration with a major pharma partner, and a solid near-term liquidity position with little traditional debt. The company is proactively building manufacturing and theranostic capabilities that could support long-term independence and scalability if its therapies succeed.

The main risks center on persistent large losses, heavy cash burn, and deeply negative equity, all of which underline dependence on external financing and successful pipeline progress. Clinical, regulatory, manufacturing, and competitive uncertainties are high, as is typical for a clinical-stage biotech. Any delays, disappointing trial results, or setbacks in manufacturing or supply could materially affect financial flexibility and strategic options.

The outlook is highly binary and driven far more by scientific and clinical milestones than by current financial performance. In the near term, the company appears funded to continue its development plans, but it remains structurally unprofitable and reliant on capital markets and partnerships. Over the medium to long term, successful clinical data, regulatory progress, and effective use of its manufacturing and partnership advantages would be needed to transform today’s high-risk, R&D-heavy profile into a sustainable commercial business.